Finding Better Health Outcomes After Retinoblastoma Treatment

Recruiting · Retinoblastoma and related conditions · 8 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This trial looks at health outcomes after treatment in patients with retinoblastoma, a type of eye cancer. It gathers information over time from patients and their families. This includes vision tests, tissue and saliva samples, and questionnaires. The goal is to learn more about the causes of retinoblastoma and find the best treatments for it.

The trial's ID number is NCT03932786. It is not a drug or device trial regulated by the FDA. The trial aims to include about 900 participants.

Who can join

Patients can join if they are diagnosed with unilateral or bilateral intraocular retinoblastoma between the ages of 0 to 17. They must have been diagnosed on or after January 1, 2008. Patients must be at least 6 months after treatment to be in the retrospective group. The prospective group must not have started treatment yet. Siblings who are not affected by retinoblastoma may also join. Everyone must be able to communicate in English, French, or Spanish.

Conditions

Retinoblastoma, Cancer Survivor, Biological Sibling, Intraocular Retinoblastoma, Unilateral Retinoblastoma

Age group

All ages

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be placed into one of two groups: a retrospective group or a prospective group. Both groups will provide saliva and tissue samples, undergo vision assessments, and complete questionnaires. Patients in the retrospective group will have assessments starting at least 6 months after their treatment. The prospective group will begin assessments at the time they enroll and continue after treatment.